Pfizer (NYSE:PFE) has been an extremely generous company in the past when it comes to returning capital. It is not alone as a mega-cap pharma company, of course, but PFE has spent a bit more heavily than others when it comes to taking care of shareholders. The dividend gets the press - perhaps unsurprisingly - but the company has also engaged in a tremendously successful buyback over the years. In this article, we'll walk through just how well PFE has done for shareholders through its "other" capital return program.
Pfizer Isn't Just A Dividend Stock
4/12/17
By Josh Arnold, SeekingAlpha
Stories you Need to Know
- David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
- Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
- MTBC Reports Record Full Year 2020 Results
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
- Merck to Acquire Pandion Therapeutics
- Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

